Brief: 4Dmt Advances 4D-710 To Phase 2 With Additional Funding
13/10/2025 13:03
Oct 13 (Reuters) - 4D Molecular Therapeutics Inc FDMT.O: 4DMT ADVANCES 4D-710 TO PHASE 2 WITH ADDITIONAL FUNDING AND SUPPORT FROM THE CYSTIC FIBROSIS FOUNDATION 4D MOLECULAR THERAPEUTICS INC - CF FOUNDATION TO INVEST UP TO $11 MILLION IN 4DMT EQUITY IN 2 TRANCHES Source text: ID:nGNXkZ8Dm Further company coverage: FDMT.O (Reporting by Anhata Rooprai) ((Anhata.Rooprai@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings